SCHEMBL19970851

SCHEMBL19970851

O=C(O)Cc1ccc2[nH]c(C(c3ccccc3)c3ccccc3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.48
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
F7 P08709 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40
GAA P10253 2/20 0.39
GRIN2D O15399 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970799 0.85 MAPK1 (0.41) KDM4EKMT2AMEN1ALDH1A1HSD17B10
SCHEMBL19970842 0.80 MLKL (0.50) KDM4EKMT2AMEN1ALDH1A1HPGD
SCHEMBL7468723 0.77 PPARG (0.58) PPARGKDM4EKMT2AMEN1ALDH1A1
Hydrochloric Acid SCHEMBL7231022 0.76 PPARG (0.57) PPARGKDM4EKMT2AMEN1ALDH1A1
SCHEMBL7033886 0.75 ALDH1A1 (0.42) KDM4EKMT2AALDH1A1MAPTHPGD
SCHEMBL3597284 0.75 MEN1 (0.54) PPARGKDM4EKMT2AMEN1ALDH1A1
SCHEMBL8909197 0.75 ALDH1A1 (0.54) PPARGKDM4EKMT2AMEN1ALDH1A1
SCHEMBL18689828 0.75 MLKL (0.49) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL391665 0.74 CYP1A2 (0.41) PPARGKDM4EKMT2AMEN1ALDH1A1
SCHEMBL19970800 0.74 CBFB (0.51) ALDH1A1HPGDCYP1A2GAAIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
EP-3512838-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION Centre National De La Recherche Scientifique (FR) 2019-07-24 EP disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS PPARG 3783/4885KDM4E 1873/4885KMT2A 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.